Local biotech's new ALS drug drives profitability six months straight

By Rowan Walrath • Published August 14, 2023 • Updated on August 14, 2023 at 9:00 am

Since its U.S. approval last fall, the amyotrophic lateral sclerosis drug made by Amylyx Pharmaceuticals Inc., has turned its maker into a profitable company — and kept that streak going for six months straight.

Amylyx started selling the ALS drug, Relyvrio, in the U.S. in late 2022. Shortly after, the company turned a $1.6 million profit for the first quarter of 2023. In the second quarter, reported by the company last week, Amylyx increased that nearly 14-fold, posting a $22.1 million profit, all driven by Relyvrio sales.

WATCH ANYTIME FOR FREE